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Abstract: Degradation of insulin was studied in this work. Casein and protamine could 
obviously suppress degradation of insulin by intestinal enzymes, and could protect 
insulin from degradation by the mechanism of competition and combination with 
proteolysis enzyme. What is more, co-incubated with HP-β-CD-casein or 
HP-β-CD-protamine, most insulin was protected from degradation by intestinal enzymes. 
In addition, it was found that the complexation of insulin with HP-β-CD was 
characterized by UV absorption spectra. These results indicated that HP-β-CD, casein 
and protamine could offer some positive and useful results, and could protect insulin 
from degradation during their transit through the intestinal tract.   
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1. Introduction 
Insulin has been in therapeutic use for almost 80 years, it has been the most effective and durable 
drug in the treatment of advanced-stage diabetes [1]. Despite significant advancements in the 
pharmaceutical research field, development of a proper non-invasive insulin delivery system remains a 
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major challenge [2-4]. The oral route represents the most convenient way of drug administration due to 
high patient compliance and comfort. One of the most important characteristics of oral delivery of 
peptides and proteins is the need to protect these drugs from proteolytic attack during their transit 
through the gastrointestinal (GI) tract [5]. Therefore, in order to overcome the enzymatic barriers, 
various approaches have been developed such as the utilization of enzyme inhibitors [6, 7] and 
functional polymers [8-10]. However, enzyme inhibitors show several safety problems for clinical 
applications, a safe and convenient way which can protect insulin from degradation by enzymes in the 
intestines is an important aspect to be considered. 
Casein is the predominant phosphoprotein, accounting for nearly 80% of proteins in milk. Casein 
consists of a fairly high number of tyrosine (Tyr) residues. Tyr residue is the cleavage site of 
α-chymotrypsin. At the same time, protamine is an alkaline protein refined from milt. Some 90% of 
amino acid residues in protamine are arginine (Arg) residues. Arg residue is one of the cleavage sites 
of trypsin. The cleavage sites of enzymatic recognizability in the two proteins are much more than 
those in insulin. It was reported that casein could protect other proteins from degradation by trypsin 
[11-13]. Therefore, casein and protamine were used to evaluate the protection of enzyme degradation 
in this paper. 
Cyclodextrins (CDs) are cyclic oligosaccharides composed of dextrose units joined through 
α-1,4-glucosidic bonds [14]. They and their derivatives have been widely used in drug delivery 
application due to their capability of forming complexes with drug molecular [15-17]. These 
complexes are able to alter the release pattern, increase the solubility and the stability of drugs. CD 
derivatives, such as HP-β-CD, could prevent insulin from self-aggregating at neutral pH [18]. It also 
displayed osmotic properties in aqueous solutions depending on their chemical structure and total 
degree of substitution [19]. Rosa et al. [20] reported that the formation of insulin/ HP-β-CD complexes 
inside microspheres achieved an effective modulation of insulin release rate. In this study HP-β-CD 
was investigated whether it could increase the stability of insulin. 
Taking this information into account, the aim of this study was to combine the virtues of casein and 
protamine with that of HP-β-CD in order to suppress degradation of insulin by intestinal proteases. In 
this work, the effect of casein, protamine and HP-β-CD on the protection of insulin from enzyme 
degradation was studied. Subsequently, co-incubation with HP-β-CD-casein or HP-β-CD-protamine 
was determined in vitro. 
 
2. Results and Discussion 
 
2.1. Effects of HP-β-CD and casein on degradation of insulin induced by α-chymotrypsin 
 
α-Chymotrypsin is a common protease in the intestine, so degradation of insulin by α-chymotrypsin 
was investigated in vitro. The remaining insulin was measured by HPLC (Figure 1) and PAGE (Figure 
2). The results using both detection methods were consistent. As shown in Figures 1 and 2, insulin was 
degraded rapidly by α-chymotrypsin, and most of insulin was degraded after 60 min. In order to 
examine whether HP-β-CD and casein could protect insulin from degradation or not, HP-β-CD and 
casein was examined, respectively. Int. J. Mol. Sci. 2008, 9                 
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Figure 1. Percentage of the remained insulin against α-chymotrypsin at 37 ºC. ◆-◆ 
Insulin + α-chymotrypsin; ■—■ Insulin + HP-β-CD +α-chymotrypsin; ▲-▲ Insulin + 
Casein + α-chymotrypsin;  Χ—Χ Insulin + Casein + HP-β-CD +α-chymotrypsin, n=3, 
mean ± SD. 
bp < 0.01,
 cp < 0.001 vs insulin + α-chymotrypsin solution according to paired 
t-test. 
 
 
Figure 2. Effects of HP-β-CD and casein on degradation of insulin induced by 
α-chymotrypsin. Lanes 1-5 in (A) represent insulin incubated with α-chymotrypsin at 37 ºC 
for 0, 15, 30, 45 and 60 min, respectively; Lanes 1-5 in (B) represent insulin incubated 
with α-chymotrypsin and HP-β-CD at 37ºC for 0, 15, 30, 45 and 60 min, respectively; 
Lanes 1-5 in (C) represent insulin incubated with α-chymotrypsin and casein at 37 ºC for 0, 
15, 30, 45 and 60 min, respectively; Lanes 1-5 in (D) represent insulin incubated with 
α-chymotrypsin, HP-β-CD and casein at 37 ºC for 0, 15, 30, 45, 60 min, respectively. 
 
(   A   )                               (   B   )  
 
                          (   C   )                                        (   D   )              Int. J. Mol. Sci. 2008, 9                 
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About 25% of the insulin was detected when it was treated with HP-β-CD, and about 45% of the 
insulin remained undegraded when it was treated with casein. About 80% insulin remained undegraded 
when it was co-incubated with HP-β-CD and casein. From statistical analysis, it was found that effects 
of HP-β-CD had no statistical significance (P>0.05), while effects of casein had distinctly statistical 
significance (P<0.01), and effects of HP-β-CD-casein had very distinctly statistical significance 
(P<0.001). It indicated that HP-β-CD had little effect, casein had advantage on the protection of insulin, 
and the two compositions could concurrently protect insulin from degradation by α-chymotrypsin. In 
addition, the remained insulin against α-chymotrypsin in the solution containing casein and protamine 
was almost equal to that in the solution containing casein (data not shown). This suggested that 
protamine had no effect on protecting insulin from degradation by α-chymotrypsin.  
 
2.2. Effects of HP-β-CD and protamine on degradation of insulin induced by trypsin 
 
To further characterize degradation of insulin by the intestinal enzyme, insulin was incubated in the 
presence of trypsin which was another common protease in the intestine. The results are shown in 
Figures 3 and 4. The amount of insulin decreased with incubation time from 0 to 60 min, and only 
about 15% of insulin remained after 60 min. The degradation was partly inhibited when insulin was 
treated with HP-β-CD, but from statistical analysis it was found that the effectsbof HP-β-CD had no 
statistical significance (P>0.05). At the same time, insulin degradation was significantly decreased 
when incubated in the presence of protamine (P<0.05). When insulin was co-incubated with HP-β-CD 
and protamine, it was shown that about 70% insulin was detected at 60 min (P<0.01), and the amount 
of remained insulin was significantly increased. In addition, the remaining insulin against trypsin in the 
solution containing casein and protamine was almost equal to that in the solution containing protamine 
(data not shown). This suggested that protamine and casein had no concurrent in protecting insulin 
from degradation by trypsin. 
Casein and protamine are natural proteins. It was showed that casein and protamine could protect 
insulin from enzymatic degradation in this study. These results were consistent with the research by Qi 
et al. [21]. As shown in Figure 5, the cleavage sites of insulin by α-chymotrypsin and trypsin were 
identified [22]. α-Chymotrypsin appeared to cleave initially at the carboxyl side of the B26-Tyr and 
A19-Tyr residues. In addition, cleavage at B16-Tyr, B25-Phe, and A14-Tyr residues was also happened 
rapidly. There were four Tyr residues (A14, A19, B16, B26) in the five cleavage sides. The amount of 
Tyr residues α-chymotrypsin recognized in the casein is much more than those in insulin. At the same 
time, trypsin cleaved insulin at the B29-Lys and B22-Arg residues. The degradation productions that 
cleaved in B29-Lys by trypsin had insulin-like activity. However, the desoctapepide cleaved in 
B22-Arg lost the activity. B22-Arg residue was essential to achieve greater stability without losing 
activity. More than 90% amino acid residues are Arg residues in protamine. Therefore, casein and 
protamine could protect insulin from degradation by the mechanism of competition and combination 
with proteolysis enzymes.      
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Figure 3. Percentage of the remained insulin against trypsin at 37 ºC. ■—■ Insulin + 
trypsin; ▲-▲ Insulin + HP-β-CD + trypsin; Δ—Δ Insulin + protamine + trypsin; *-* 
Insulin +protamine + HP-β-CD + trypsin. n=3, mean ± SD. 
bp < 0.05,
 cp < 0.01 vs insulin + 
trypsin solution according to paired t-test. 
 
Figure 4.  Effects of HP-β-CD and protamine on degradation of insulin induced by 
trypsin. Lanes 1-5 in (A) represent insulin incubated with trypsin at 37 ºC for 0, 15, 30, 45 
and 60 min, respectively; Lanes 1-5 in (B) represent insulin incubated with trypsin and 
HP-β-CD at 37 ºC for 0, 15, 30, 45 and 60 min, respectively; Lanes 1-5 in (C) represent 
insulin incubated with trypsin and protamine  at 37 ºC for 0, 15, 30, 45 and 60 min, 
respectively;  Lanes 1-5 in (D) represent insulin incubated with trypsin, HP-β-CD and 
protamine at 37 ºC for 0, 15, 30, 45 and 60 min, respectively. 
 
(   A   )                                (   B   )  
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Figure 5. The cleavage site of insulin by proteases. A: The sites are the recognized site of 
α- chymotrypsin; B : The sites are the recognized sites of trypsin. 
 
 
2.3. UV absorption spectra of insulin in different solutions 
 
The absorption spectra of insulin in different solutions are shown in Figure 6, Table 1 and Table 2. 
Adding HP-β-CD to the insulin solution resulted in a significant enhancement of the UV absorption 
spectra at wavelength from 250 to 300 nm. However, the max. absorption wavelength at 275 nm was 
not changed. This indicated that the complexation of insulin with HP-β-CD existed. The absorption 
spectrum of insulin in the solution containing casein was the sum of the absorption spectrum of insulin 
and that of casein. At the same time, the absorption spectrum of insulin at 275 nm wavelength in the 
solution containing casein and HP-β-CD was the sum of the absorption spectrum of insulin in the 
solution containing HP-β-CD and that of casein (Table 1). This indicated that insulin and casein were 
merely mixed, not complexed. From Figure 6B, it was found that the absorption spectrum of 
protamine at 275 nm wavelength had not a max. absorption, due to little aromatic amino acids in 
protamine. The absorption spectrum of insulin in the solution containing protamine was not the sum of 
the absorption spectrum of insulin and that of protamine. Furthermore, the absorption spectrum of 
insulin in the solution containing protamine and HP-β-CD was lower than the absorption spectrum of 
insulin in the solution containing HP-β-CD (Table 2). It suggested that insulin and protamine might be 
combined. Insulin is with positive charge at pH 7.0 buffer, however, protamine is with negative charge 
at pH 7.0 buffer. Therefore, insulin and protamine might be integrated.   
CDs are well known molecular entities used as pharmaceutical excipients mainly to solubilize and 
stabilize drugs through complexation [23]. The interaction between insulin and CDs had been studied 
mostly on absorption enhancement effects through skin, nasal and pulmonary mucus membranes [14, 
24]. The UV absorption spectra experiment indicated that the complexation between HP-β-CD and 
insulin existed. Previously, it was found that β-CD could include insulin easily in neutral water 
solution in our laboratory [25]. Sajeesh et al. [17] and Rosa et al. [20] confirmed the formation of 
HP-β-CD and insulin complexes, using FTIR and fluorescence spectroscopic analysis. Moreover, 
Dotsidas et al. [1] reported that the interaction of insulin with methyl-beta cyclodextrin improves its 
stability, but Shao et al. [26] showed that hydroxypropyl-β-cyclodextrin did neither increase oral Int. J. Mol. Sci. 2008, 9                 
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bioavailability of insulin, nor it could protect insulin from α-chymotrypsin degradation. In the present 
study, it was found that HP-β-CD had a little effect of improving the stability of insulin in the intestinal 
proteases  in vitro, but the effect had no statistical significance. These results were not entirely 
consistent. The causes may be correlated with the concentration of proteases.   
 
Figure 6. UV absorption spectra of insulin in different solutions. Curves 1-5 in (A) 
represent insulin, Insulin (100 μg/mL) + HP-β-CD (1 mg/mL), Casein (200 μg/mL), 
Insulin (100 μg/mL) + Casein (200 μg/mL), Insulin (100 μg/mL)+ Casein (200 μg/mL) + 
HP-β-CD (1 mg/mL), respectively; Curves 1-5 in (B) represent protamine (200 μg/mL), 
insulin (100 μg/mL), insulin (100 μg/mL) + protamine (200 μg/mL), insulin (100 μg/mL) + 
protamine (200 μg/mL) + HP-β-CD (1 mg/mL), insulin (100 μg/mL) + HP-β-CD (1 
mg/mL), respectively. 
 
 
( A ) 
 
( B ) Int. J. Mol. Sci. 2008, 9                 
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Table 1. The absorption of insulin and casein. 
Component in the solution ΔA275
Insulin 0.098 
Insulin + HP-β-CD 0.102 
Casein 0.219 
Insulin + Casein  0.317 
Insulin + Casein + HP-β-CD 0.321 
 
Table 2. The absorption of insulin and protamine. 
Component in the solution ΔA275
protamine 0.006 
Insulin 0.096 
Insulin + protamine  0.098 
Insulin+protamine+HP-β-CD 0.099 
Insulin + HP-β-CD 0.101 
 
3. Experimental Section   
 
3.1. Materials 
 
Insulin (nominal activity: 28 IU/mg) was purchased from Xuzhou Wanbang Biopharma Company 
(P.R. China), HP-β-CD (MW:1380 Da) was obtained from Sigma Chemical Co. (USA). 
α-Chymotrypsin (4000 U/mg), trypsin (25,000 U/g), casein and protamine were purchased from 
Shanghai Biochemistry Pharma Company (P.R. China). Acetonitrile was HPLC grade, and all other 
reagents used were of analytical grade and commercially available. 
 
3.2. HPLC method 
 
HPLC was carried out according to Todo et al. [27] with minor modifications. Analyses of 
remaining insulin were carried out by reserve phase HPLC with an isocratic system (Shimadzu Co., 
Kyoto) using the raw insulin bulk drug as the standard (28 IU/mg). The HPLC system was composed 
of a pump (LC-10ADvp), diode array detector (SPD-M10Avp), column oven (CTO-10ASvp), and LC 
workstation (CLASS-LC10). The mobile phase was a 72:28 mixture of 0.2 mol/L sodium sulphate 
buffer (pH 3.0) and acetonitrile at a flow rate of 1.0 mL/min. The column was a Shodex Asahipak 
ODP-50 6D (4.6mm × 150 mm, 5 um) (Showa Denko, Ltd., Tokyo) heated at room temperature. 
Ultraviolet absorption was measured at 214 nm. 
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3.3. Polyacrylamide gel electrophoresis (PAGE) 
 
PAGE was carried out according to Laemmli [28] with minor modifications. The running gel, 
stacking gel and electrode buffer are without sodium dodecyl sulfate (SDS). The running gel and 
stacking gel contained 15% and 4.5% acrylamide, respectively. After electrophoresis, the gels were 
subjected to stain with Coomassie Brilliant R-250. 
 
3.4. Degradation of insulin induced by α-chymotrypsin and trypsin 
 
Insulin was dissolved in a few drops of 0.05 mol/L HCL, then 0.05 mol/L PBS (phosphate buffer, 
pH=7.0) was added. α-Chymotrypsin (5 mg/mL) and trypsin (12 mg/mL) solutions were prepared with 
Tris-HCL buffer (pH=8.0), respectively. Casein (5 g) was dissolved in 0.1 mol/L NaOH (10 mL), then 
was diluted to 100 mL with PBS (pH=7.0), The pH of final concentration was again measured and 
adjusted to pH 7.0. 5% Protamine solution was prepared with PBS (pH=7.0). Insulin solution and 
enzyme solutions were incubated at 37 ºC for 15 min. Different treatments were administered. The 
final concentration of insulin in the solution was 0.5 mg/mL. The final mass ratios in the solution were 
as following, insulin:HP-β-CD = 1 :30; insulin:casein = 1:10; insulin:protamine = 1:10; insulin:casein 
or protamine:HP-β-CD = 1:10:30. Before the addition of a-chymotrypsin solution, insulin solution was 
vortexed at high speed for 5 s and a sample was withdrawn and added with ice-cold 0.5% TFA acid as 
the zero time sample. Samples were withdrawn for 15, 30, 45 and 60 min after the addition of the 
enzyme solution at 37 ºC. The final enzyme concentrations of α-chymotrypsin and trypsin were 8 
mg/L [29] and 600 mg/L [21], respectively. Then the samples were analyzed by PAGE and HPLC after 
adding 50 μl of ice-cold 0.5% TFA acid to terminate the reaction. Every experiment was carried out 
three times. The average and the standard deviation of the data were calculated. 
 
3.5. Spectroscopic methods 
 
Absorption spectra were recorded on a Shimadzu UV-2450 spectrophotometer. The absorption 
spectra were carried out according to Kano et al. [30]. 
 
4. Conclusions 
 
Insulin is ineffective by oral administration due to the low stability in the GI and their poor 
absorption [31]. Therefore, it is essential for oral insulin delivery system to protect insulin from 
enzymatic degradation. In this study, it was also found that insulin was very sensitive to these 
proteases in the intestine. Furthermore, casein and protamine could partly suppress degradation of 
insulin in the intestinal proteases in vitro, and could protect insulin from degradation by the 
mechanism of competition and combination with proteolysis enzymes. In addition, it was found that 
the complexation of insulin with HP-β-CD was characterized by UV absorption spectra. When the 
complexes were co-incubated with casein or protamine, most insulin was protected from the enzymatic 
degradation. In addition, HP-β-CD and casein had synergic effects on protection of insulin from 
enzymatic degradation. Int. J. Mol. Sci. 2008, 9                 
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Casein and protamine which are esculent and nontoxic proteins had obvious advantages in 
protecting insulin from enzymatic degradation. At the same time, HP-β-CD is also a safe drug additive. 
The present study combined the virtues of casein and protamine with that of HP-β-CD to protect 
insulin from enzymatic degradation. Taken together, HP-β-CD, casein and protamine could offer some 
positive and useful results, and could be an efficient way to achieve the oral delivery of insulin. 
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